Clinical Trial

Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 12, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The primary aim of the study is to show that methoxyflurane-lorazepam-percocet combination administrated 'per os' is non inferior to deep intravenous sedation in achieving analgesia during Rezum convective radiofrequency water vapor thermal therapy for the management of benign prostate hyperplasia (BPH). We propose to conduct a single-centered, unblinded, randomized controlled trial designed after consulting ICH Guidelines for Good Clinical Practice as well the regulations set by the Biomedical Research Ethics Board, University of Manitoba.
Trial Details
NCT Number NCT07017452
Lead Sponsor University of Manitoba
Conditions Benign Prostate Hypertrophy(BPH)
Enrollment 48 participants
Start Date 2025-08
Primary Completion 2025-12 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-06-12